Parisa Soleimani
1 
, Sepideh Yadollahifarsani
1 , Mahsa Motieian
2 , Mahshid Sadat Chenarani Moghadam
3 , Shahrzad Alimohammadi
4,5 , Azadeh Khayyat
6 , Mohammad Ali Esmaeil Pour
7 , Sina Neshat
8 , Narges Alsadat Marashi
9 , Leila Mahmoodnia
10* , Rohollah Masomi
10* 1 Nickan Research Institute, Isfahan, Iran
2 Independent Researcher, Dobbs Ferry, NY, United States
3 Department of Dermatology, Radboud University Medical Center, Nijmegen, the Netherlands
4 Doctoral School of Molecular Medicine, University of Debrecen, Debrecen, Hungary
5 Department of Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
6 Department of Pathology, Resident Physician, Medical College of Wisconsin, Milwaukee, WI, USA
7 Department of Internal Medicine, Resident Physician, University of NC Health Blue Ridge, Morganton, NC, USA
8 Department of Pulmonology, Mayo Clinic, Jacksonville 32224 FL, USA
9 Faculty of Life Sciences, University of Strasbourg, Strasbourg, France
10 Cancer Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
Abstract
COVID-19 infection has been a global health issue in the past recent years and numerous topics are studied in order to discover its pathophysiology and potential side effects. The potential for disease recurrence following the administration of the COVID-19 vaccine is one of the issues that has recently attracted attention. Several studies have revealed that the COVID-19 vaccines, like other vaccines, may have side effects and, in some cases, they may even deteriorate the underlying illnesses, such as rheumatic diseases, autoimmune diseases, and cancers. The effectiveness and safety of the COVID-19 vaccine for patients with malignancies are one of the factors that are considered regarding this vaccine. Lymph node involvement, disease recurrence, and potential paraclinical changes after receiving the COVID-19 vaccine are some of the concerns of patients with malignancy. In this mini-review, we attempted to investigate cases of cancer recurrence or recovery as well as lymphadenopathy following vaccination.
Implication for health policy/practice/research/medical education:
The effectiveness and safety of the COVID-19 vaccine for patients with malignancies are one of the factors that are considered regarding this vaccine.
Please cite this paper as: Soleimani P, Yadollahifarsani S, Motieian M, Chenarani Moghadam MS, Alimohammadi S, Khayyat A, Esmaeil Pour MA, Neshat S, Marashi NA, Mahmoodnia L, Masomi R. Cancer recurrence or aggravation following COVID-19 vaccination. J Nephropharmacol. 2023;12(2):e10593. DOI: 10.34172/npj.2023.10593.